Recro Pharma, Inc. (REPH): Price and Financial Metrics


Recro Pharma, Inc. (REPH): $2.09

-0.01 (-0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

REPH Stock Price Chart Interactive Chart >

Price chart for REPH

REPH Price/Volume Stats

Current price $2.09 52-week high $3.79
Prev. close $2.10 52-week low $1.38
Day low $2.00 Volume 141,800
Day high $2.14 Avg. volume 126,298
50-day MA $1.71 Dividend yield N/A
200-day MA $1.89 Market Cap 117.93M

Recro Pharma, Inc. (REPH) Company Bio


Recro Pharma is a clinical stage specialty pharmaceutical company, engaging in developing non-opioid therapeutics for the treatment of pain. The company was founded in 2007 and is based in Malvern, Pennsylvania.


REPH Latest News Stream


Event/Time News Detail
Loading, please wait...

REPH Latest Social Stream


Loading social stream, please wait...

View Full REPH Social Stream

Latest REPH News From Around the Web

Below are the latest news stories about Recro Pharma Inc that investors may wish to consider to help them evaluate REPH as an investment opportunity.

Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

Full Scope of New Service Capabilities to be Operational in Q2; Company Has Already Secured Project Commitments from Multiple New ClientsSAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophil

Yahoo | February 23, 2022

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. EasternSAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market

Yahoo | February 22, 2022

Recro Pharma (NASDAQ:REPH) investors are sitting on a loss of 80% if they invested three years ago

As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...

Yahoo | February 8, 2022

Frontier Wealth Management LLC Buys Rio Tinto PLC, T-Mobile US Inc, Raytheon Technologies Corp, ...

Kansas City, MO, based Investment company Frontier Wealth Management LLC (Current Portfolio) buys Rio Tinto PLC, T-Mobile US Inc, Raytheon Technologies Corp, Recro Pharma Inc, New Relic Inc, sells Goldman Sachs Just Us Large Cap Equity ETF, Invesco BulletShares 2021 Corporate Bond ETF, United Parcel Service Inc, MGP Ingredients Inc, Silvergate Capital Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Frontier Wealth Management LLC.

Yahoo | February 4, 2022

Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government. The contract focuses on supporting clinical devel

Yahoo | January 26, 2022

Read More 'REPH' Stories Here

REPH Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 42.18%
3-year -87.39%
5-year -76.00%
YTD N/A
2022 0.00%
2021 -40.00%
2020 -84.45%
2019 158.17%
2018 -23.24%

Continue Researching REPH

Want to see what other sources are saying about Recro Pharma Inc's financials and stock price? Try the links below:

Recro Pharma Inc (REPH) Stock Price | Nasdaq
Recro Pharma Inc (REPH) Stock Quote, History and News - Yahoo Finance
Recro Pharma Inc (REPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7027 seconds.